课题基金 / 基金详情

ORAL INTERFERON ALPHA--EFFECTS IN RELAPSING REMITTING MULTIPLE SCLEROSIS

ORAL INTERFERON ALPHA--EFFECTS IN RELAPSING REMITTING MULTIPLE SCLEROSIS
口服干扰素α——对多发性硬化症复发缓解的作用
批准号：
6309256
负责人：
STALEY armstrong BROD
金额：
$1.51万
依托单位：
UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON
依托单位国家：
美国
项目类别：
财政年份：
1999
资助国家：
美国
项目状态：
已结题
起止时间：
1999-12-01 至 2001-02-28
来源：
https://reporter.nih.gov/project-details/6309256
关键词：
clinical research dosage human subject human therapy evaluation immunotherapy interferon alpha interferon gamma magnetic resonance imaging multiple sclerosis oral administration

项目摘要

项目成果

STALEY armstrong BROD的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
The purpose of this phase II study is to determine whether oral interferon-alpha (IFN-a) can decrease enhancing lesions on brain MRI (paraclinical outcome) and IFN-gamma secretion (immunological outcome) in patients with relapsing remitting multiple sclerosis (MS). Patients will be randomized to receive placebo, 10,000 or 30,000 units on alternate days for nine months. If IFN-a shows immunological, MRI paraclinical effects or toxicity in subjects, it will provide dosing information essential to evaluate the drug in future studies as a treatment in MS patients.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
IFNA: PROLONGATION OR PERMANENCE OF THE "HONEYMOON" PHASE IN DIABETES MELLITUS
PREVENTION OF COGNITIVE DECLINE IN ALZHEIMER'S DISEASE VIA INGESTED IFN-ALPHA
PROTEIN BIOMARKERS OF IFN-ALPHA IN MS
INGESTED IFN-A: PROLONGATION OR PERMANENCE OF THE "HONEYMOON" PHASE IN DIABETES
海外基金